IRBs Should Not Be Privy To Prior Review Board Decisions, PhRMA Says
Executive Summary
Clinical investigators and sponsors should not be required to inform institutional review boards about previous IRB review decisions, the Pharmaceutical Research & Manufacturers of America maintains in June 3 comments to FDA